Startups
QL Biopharm is a biopharmaceutical company that focuses on developing and commercializing innovative drugs for the treatment of cancer and other diseases. The company’s products include QL-, QL-, QL-, QL-, and QL-.
According to Mordor Intelligence, the biopharmaceuticals market is estimated to be USD 407.72 billion in the current year and it is expected to reach USD 651.78 billion by the end of the forecast period, registering a CAGR of 8.03%.
According to Mordor Intelligence, the biopharmaceuticals market is estimated to be USD 407.72 billion in the current year and it is expected to reach USD 651.78 billion by the end of the forecast period, registering a CAGR of 8.03%.
Overview
Location
China, Chongqing, Changping
Employees
51-200
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 18, 2025 | QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025 | Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg every other week (12.5%) The overall safety... |
| Jul 30, 2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms. When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| Nov 28, 2023 | Deals in brief: Jala Tech confirms Series A funding, Neuralink secures additional USD 43 million, multiple China and India deals, and more | Jala Tech confirms closure of Series A round Following DealStreetAsia’s report on November 27 regarding Jala Tech completing its Series A funding round, the Indonesian aquaculture tech company has released a statement today confirming the m... |
| QL Biopharma | “living things.” |
Reviews 0
FAQ about 质肽生物
What has the press written about 质肽生物?
Parsers VC has collected 5 articles mentioning 质肽生物, among them “QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025” (Sep 18, 2025) and “Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease?” (Jul 30, 2024).
Is 质肽生物 still active?
Yes, 质肽生物 is active; its latest activity on Parsers VC dates from Mar 3, 2026.